13.01
price down icon2.40%   -0.32
 
loading
Teladoc Health Inc stock is currently priced at $13.01, with a 24-hour trading volume of 7.61M. It has seen a -2.40% decreased in the last 24 hours and a -13.55% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $13.37 pivot point. If it approaches the $12.82 support level, significant changes may occur.
Previous Close:
$13.33
Open:
$12.68
24h Volume:
7.61M
Market Cap:
$2.20B
Revenue:
$2.60B
Net Income/Loss:
$-220.37M
P/E Ratio:
-0.5276
EPS:
-24.66
Net Cash Flow:
$193.67M
1W Performance:
+0.23%
1M Performance:
-13.55%
6M Performance:
-19.14%
1Y Performance:
-49.51%
1D Range:
Value
$12.65
$13.60
52W Range:
Value
$12.65
$30.41

Teladoc Health Inc Stock (TDOC) Company Profile

Name
Name
Teladoc Health Inc
Name
Phone
203-635-2002
Name
Address
2 Manhattanville Road, Suite 203, Purchase, NY
Name
Employee
2,032
Name
Twitter
@teladoc
Name
Next Earnings Date
2024-05-23
Name
Latest SEC Filings
Name
TDOC's Discussions on Twitter

Teladoc Health Inc Stock (TDOC) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-17-24 Downgrade DA Davidson Buy → Neutral
Jan-03-24 Initiated Barclays Overweight
Apr-12-23 Initiated Stephens Equal-Weight
Feb-23-23 Upgrade SVB Securities Market Perform → Outperform
Oct-24-22 Upgrade Guggenheim Sell → Neutral
Sep-16-22 Initiated KeyBanc Capital Markets Sector Weight
Sep-07-22 Initiated Truist Hold
Aug-17-22 Downgrade Guggenheim Neutral → Sell
Aug-12-22 Initiated DA Davidson Buy
Aug-02-22 Downgrade Berenberg Buy → Hold
Aug-02-22 Downgrade Cowen Outperform → Market Perform
Jul-28-22 Downgrade Goldman Buy → Neutral
Jul-28-22 Downgrade Needham Buy → Hold
Jul-06-22 Reiterated BofA Securities Neutral
May-05-22 Downgrade Argus Buy → Hold
Apr-28-22 Downgrade Citigroup Buy → Neutral
Apr-28-22 Downgrade Credit Suisse Outperform → Neutral
Apr-28-22 Downgrade Guggenheim Buy → Neutral
Apr-28-22 Downgrade JP Morgan Overweight → Neutral
Apr-28-22 Downgrade SVB Leerink Outperform → Mkt Perform
Apr-28-22 Downgrade Wells Fargo Overweight → Equal Weight
Apr-28-22 Downgrade William Blair Outperform → Mkt Perform
Apr-07-22 Initiated Guggenheim Buy
Apr-01-22 Resumed Credit Suisse Outperform
Mar-03-22 Upgrade Argus Hold → Buy
Feb-23-22 Reiterated BofA Securities Neutral
Feb-23-22 Reiterated Craig Hallum Hold
Feb-23-22 Reiterated Evercore ISI In-line
Feb-23-22 Reiterated Goldman Buy
Feb-23-22 Reiterated JP Morgan Overweight
Feb-23-22 Reiterated KeyBanc Capital Markets Overweight
Feb-23-22 Reiterated Needham Buy
Feb-23-22 Reiterated Oppenheimer Outperform
Feb-23-22 Reiterated Stifel Hold
Feb-11-22 Initiated Goldman Buy
Feb-08-22 Reiterated Piper Sandler Overweight
Dec-02-21 Resumed Jefferies Hold
Nov-22-21 Downgrade BTIG Research Buy → Neutral
Oct-28-21 Reiterated Barclays Equal Weight
Oct-28-21 Reiterated BofA Securities Neutral
Oct-28-21 Reiterated Canaccord Genuity Buy
Oct-28-21 Reiterated Citigroup Buy
Oct-28-21 Reiterated Craig Hallum Hold
Oct-28-21 Reiterated Needham Buy
Oct-28-21 Reiterated Oppenheimer Outperform
Oct-28-21 Reiterated Piper Sandler Overweight
Oct-28-21 Reiterated UBS Neutral
Oct-19-21 Initiated Wells Fargo Overweight
Aug-02-21 Downgrade Argus Buy → Hold
Jul-28-21 Downgrade Deutsche Bank Buy → Hold
May-28-21 Initiated Robert W. Baird Neutral
Apr-15-21 Initiated Needham Buy
Jan-07-21 Initiated BTIG Research Buy
Dec-22-20 Initiated Evercore ISI In-line
Dec-07-20 Downgrade Stephens Overweight → Equal-Weight
Dec-04-20 Initiated Goldman Neutral
Nov-13-20 Upgrade Robert W. Baird Neutral → Outperform
Sep-22-20 Initiated DA Davidson Buy
Sep-02-20 Upgrade Berenberg Hold → Buy
Aug-17-20 Upgrade Credit Suisse Neutral → Outperform
Jul-14-20 Initiated Citigroup Buy
Jul-13-20 Initiated Argus Buy
Jul-07-20 Initiated Stephens Overweight
Apr-30-20 Reiterated KeyBanc Capital Markets Overweight
Apr-13-20 Initiated SVB Leerink Outperform
Mar-31-20 Downgrade Berenberg Buy → Hold
Mar-25-20 Downgrade Craig Hallum Buy → Hold
Mar-16-20 Upgrade KeyBanc Capital Markets Sector Weight → Overweight
Mar-12-20 Downgrade Robert W. Baird Outperform → Neutral
Feb-28-20 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Feb-12-20 Downgrade Wells Fargo Overweight → Equal Weight
Jan-10-20 Initiated UBS Neutral
Jan-09-20 Downgrade BofA/Merrill Buy → Neutral
View All

Teladoc Health Inc Stock (TDOC) Financials Data

Teladoc Health Inc (TDOC) Revenue 2024

TDOC reported a revenue (TTM) of $2.60 billion for the quarter ending December 31, 2023, a +8.13% rise year-over-year.
loading

Teladoc Health Inc (TDOC) Net Income 2024

TDOC net income (TTM) was -$220.37 million for the quarter ending December 31, 2023, a +98.39% increase year-over-year.
loading

Teladoc Health Inc (TDOC) Cash Flow 2024

TDOC recorded a free cash flow (TTM) of $193.67 million for the quarter ending December 31, 2023, a +1,072% increase year-over-year.
loading

Teladoc Health Inc (TDOC) Earnings per Share 2024

TDOC earnings per share (TTM) was -$1.34 for the quarter ending December 31, 2023, a +98.42% growth year-over-year.
loading
Teladoc Health, Inc. provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers of Fortune 1000 companies, health plans, health systems, and other entities. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was founded in 2002 and is headquartered in Purchase, New York.
$16.57
price up icon 1.66%
$7.19
price up icon 1.55%
$32.04
price down icon 1.42%
health_information_services EVH
$27.65
price down icon 2.37%
health_information_services TXG
$27.59
price up icon 2.57%
$23.82
price up icon 0.97%
Cap:     |  Volume (24h):